Imperial College London
Portrait Picture

Professor Cleo Kontoravdi

Faculty of Engineering, Department of Chemical Engineering

Professor of Biological Systems Engineering
 
 
 
//

Contact

 

+44 (0)20 7594 6655cleo.kontoravdi98 Website

 
 
//

Location

 

310ACE ExtensionSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kis:2020:10.1002/amp2.10060,
author = {Kis, Z and Kontoravdi, K and Dey, AK and Shattock, R and Shah, N},
doi = {10.1002/amp2.10060},
journal = {Journal of Advanced Manufacturing and Processing},
pages = {1--10},
title = {Rapid development and deployment of high-volumevaccines for pandemic response},
url = {http://dx.doi.org/10.1002/amp2.10060},
volume = {2},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Overcoming pandemics, such as the current Covid19 outbreak, requires the manufacture of several billion doses of vaccines within months. This is an extremely challenging task given the constraints in smallscale manufacturing for clinical trials, clinical testing timelines involving multiple phases and largescale drug substance and drug product manufacturing. To tackle these challenges, regulatory processes are fasttracked, and rapidresponse manufacturing platform technologies are used. Here, we evaluate the current progress, challenges ahead and potential solutions for providing vaccines for pandemic response at an unprecedented scale and rate. Emerging rapidresponse vaccine platform technologies, especially RNA platforms, offer a high productivity estimated at over 1 billion doses per year with a small manufacturing footprint and low capital cost facilities. The selfamplifying RNA (saRNA) drug product cost is estimated at below 1 USD/dose. These manufacturing processes and facilities can be decentralized to facilitate production, distribution, but also raw material supply. The RNA platform technology can be complemented by an a priori Quality by Design analysis aided by computational modeling in order to assure product quality and further speed up the regulatory approval processes when these platforms are used for epidemic or pandemic response in the future.
AU  - Kis,Z
AU  - Kontoravdi,K
AU  - Dey,AK
AU  - Shattock,R
AU  - Shah,N
DO  - 10.1002/amp2.10060
EP  - 10
PY  - 2020///
SN  - 2637-403X
SP  - 1
TI  - Rapid development and deployment of high-volumevaccines for pandemic response
T2  - Journal of Advanced Manufacturing and Processing
UR  - http://dx.doi.org/10.1002/amp2.10060
UR  - https://aiche.onlinelibrary.wiley.com/doi/full/10.1002/amp2.10060
UR  - http://hdl.handle.net/10044/1/80805
VL  - 2
ER  -
Download